Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by Felcoon May 14, 2014 12:23pm
357 Views
Post# 22560833

RE:RE:RE:RE:RE:4050???

RE:RE:RE:RE:RE:4050???Staghorn,

Discussion on 4050 handled not by Pierre, but by the Chief Medical Officer.  He was openly enthusiastic about the prospects, with the final patients finishing phase 1 trials by the end of June, phase 1/2b will be initiated in the second half of 2014.  If results on phase 1/2b support the indications from the animal trials, PLI will need security protection from those beating a path to PLI's doors (his words).  He termed 4050 the diamond in PLI's portfolio.  In terms of what has been discussed, to this point of the webcast, 4050 has been a major part of it.

I was surprised by the fact that only now, the last of the patients have entered the phase 1 clinical trial.  I and I suppose yourself, would have thought this would have concluded some time earlier.  But like a previous postered mentioned, Pierre said not hearing anything with regards to phase 1 trials on 4050 is actually a good thing.

Good luck,
Felco
Bullboard Posts